Allogeneic hematopoietic stem celltransplant (HSCT) after checkpoint inhibitors (ChIs) in classic Hodgkin lymphoma (cHL): Outcome and safety in pooled analysis.

e19020Background: ChIs are highly effective in relapsed and refractory cHL. Patients undergoing HSCT after ChIs are at risk of developing severe Graft-versus-Host disease (GVHD) due to blockage of ...